# CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

> **NCT04059003** · — · UNKNOWN · sponsor: **Shengjing Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Taxanes or/and anthracycline-based therapy

## Key facts

- **NCT ID:** NCT04059003
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04059003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04059003, "CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04059003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*